4.5 Article

Detection of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Longitudinal Brain MRI

Journal

FRONTIERS IN NEUROINFORMATICS
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fninf.2017.00016

Keywords

Alzheimer's disease; Mild Cognitive Impairment (MCI); conversion; MRI; Stationary Velocity Field (SVF); non-rigid Registration; parallel Transport; SVM classification

Funding

  1. Joint Scientific Thematic Research Programme (JSTP) [116350001]
  2. Netherlands Organization for Scientific Research (NWO) [VENI 639.021.124]
  3. European Union Seventh Framework Programme (FP7) [604102]
  4. European Union's Horizon research and innovation programme [720270]
  5. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  6. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  7. National Institute on Aging
  8. National Institute of Biomedical Imaging and Bioengineering
  9. AbbVie
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Araclon Biotech
  13. BioClinica, Inc.
  14. Biogen
  15. Bristol-Myers Squibb Company
  16. CereSpir, Inc.
  17. Eisai Inc.
  18. Elan Pharmaceuticals, Inc.
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd
  22. Genentech, Inc.
  23. Fujirebio
  24. GE Healthcare
  25. IXICO Ltd.
  26. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  27. Johnson & Johnson Pharmaceutical Research & Development LLC.
  28. Lumosity
  29. Lundbeck
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC.
  32. NeuroRx Research
  33. Neurotrack Technologies
  34. Novartis Pharmaceuticals Corporation
  35. Pfizer Inc.
  36. Piramal Imaging
  37. Servier
  38. Takeda Pharmaceutical Company
  39. Transition Therapeutics
  40. Canadian Institutes of Health Research

Ask authors/readers for more resources

Mild Cognitive Impairment (MCI) is an intermediate stage between healthy and Alzheimer's disease (AD). To enable early intervention it is important to identify the MCI subjects that will convert to AD in an early stage. In this paper, we provide a new method to distinguish between MCI patients that either convert to Alzheimer's Disease (MCIc) or remain stable (MCIs), using only longitudinal T1-weighted MRI. Currently, most longitudinal studies focus on volumetric comparison of a few anatomical structures, thereby ignoring more detailed development inside and outside those structures. In this study we propose to exploit the anatomical development within the entire brain, as found by a non-rigid registration approach. Specifically, this anatomical development is represented by the Stationary Velocity Field (SVF) from registration between the baseline and follow-up images. To make the SVFs comparable among subjects, we use the parallel transport method to align them in a common space. The normalized SVF together with derived features are then used to distinguish between MCIc and MCIs subjects. This novel feature space is reduced using a Kernel Principal Component Analysis method, and a linear support vector machine is used as a classifier. Extensive comparative experiments are performed to inspect the influence of several aspects of our method on classification performance, specifically the feature choice, the smoothing parameter in the registration and the use of dimensionality reduction. The optimal result from a 10-fold cross-validation using 36 month follow-up data shows competitive results: accuracy 92%, sensitivity 95%, specificity 90%, and AUC 94%. Based on the same dataset, the proposed approach outperforms two alternative ones that either depends on the baseline image only, or uses longitudinal information from larger brain areas. Good results were also obtained when scans at 6, 12, or 24 months were used for training the classifier. Besides the classification power, the proposed method can quantitatively compare brain regions that have a significant difference in development between the MCIc and MCIs groups.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available